Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AMRI Secures Seven-year NIH Contract | Contract Pharma
Breaking News

AMRI Secures Seven-year NIH Contract

Will focus on development and manufacture of APIs

AMRI has secured a seven-year contract from the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH).

AMRI’s activities under the contract (HHSN272201800008I) will focus on the development and manufacture of active pharmaceutical ingredients (API) and drug product for Phase I clinical studies. The bulk of AMRI’s work will occur at the company’s Albany, NY, facilities.

“Our new contract with the NIH not only enhances AMRI’s ability to positively impact the health of the general public, but it also serves as a testament of our work, giving prospective customers confidence in our aptitude to solve complex scientific challenges,” said Christopher Conway, senior vice president of discovery, development and analytical services and fine chemicals, AMRI. “We are excited for the opportunity to further support this well-respected government agency aimed at advancing their researchers’ programs.”

Other programs where AMRI is contracted to provide services to NIH-funded researchers include the company’s selection as a Dedicated Chemical Biology Consortium (CBC) Center for the NCI Experimental Therapeutics (NExT) Program, the National Center for Advancing Translational Sciences (NCATS) and the Blueprint Neurotherapeutics Network.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters